Article
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
European journal of cancer (Oxford, England : 1990) - 1 Mar 2021
Jones Robin L, Serrano César, von Mehren Margaret, George Suzanne, Heinrich Michael C, Kang Yoon-Koo, Schöffski Patrick, Cassier Philippe A, Mir Olivier, Chawla Sant P, Eskens Ferry A L M, Rutkowski Piotr, Tap William D, Zhou Teresa, Roche Maria, Bauer Sebastian
Abstract excerpt
BACKGROUND: PDGFRA D842V mutations occur in 5-10% of gastrointestinal stromal tumours (GISTs), and previously approved tyrosine kinase inhibitors (TKIs) are inactive against this mutation. Consequently, patients have a poor prognosis. We present an updated analysis of avapritinib efficacy and long-term safety in this patient population. METHODS: NAVIGATOR (NCT02508532), a two-part, open-label,...
Topics
Join the communities discussing this publication.